BrainStorm Cell Therapeutics, a developer of adult stem cell therapeutics targeting Central Nervous System (CNS) neurodegenerative diseases, announced today that the company received a grant of approximately $1.1 million from Israel’s Office of the Chief Scientist. The grant is awarded to towards the development of BrainStorm’s NurOwn therapy for the neurodegenerative disease ALS – also known as Lou Gehrig’s Disease – using adult stem cells. The treatment is currently under clinical trials in Israel, with interim results expected by July 2012.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments